1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

GZPHF
Guangzhou Baiyunshan Pharmaceutical Holdings Company LimitedUS flagOther OTC
2.34
USD
- -
- -
6.20BMarket Cap
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
GZPHF
(Other OTC)

Recent

price

2.34

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.53
6.72
9.56
13.8
14.58
14.81
14.28
12.89
25.97
39.94
37.93
42.45
43.55
46.46
46.13
- -
46.6
Revenue per Share
0.33
0.35
0.58
0.77
0.92
1.01
1.08
1.27
2.12
1.96
1.79
2.29
2.44
2.49
1.74
- -
1.72
Basic EPS, GAAP
-0.01
-0.29
0.66
0.77
1.08
1.1
1.65
1.01
2.91
1.61
-0.18
2.72
3.45
1.52
1.42
- -
-0.65
Free Cash Flow per Basic Share
0.05
0.05
0.13
0.03
0.32
0.31
0.37
0.29
0.54
0.64
0.79
0.78
0.92
0.98
1.38
- -
1.09
Dividend per Share
2.23
2.51
2.44
2.84
3.37
4.01
4.57
4.82
6.43
7.87
8.95
10.59
12.23
13.89
14.42
- -
15.56
Book Value per Share
4.36
4.69
4.32
5.21
5.83
6.3
12.1
11.39
13.1
13.94
15.33
17.16
18.44
20.09
20.75
- -
21.99
Tangible Book Value per Share
812
810
1,261
1,276
1,291
1,291
1,403
1,626
1,626
1,626
1,626
1,626
1,626
1,626
1,626
- -
1,626
Basic Weighted Avg Shares
4,486
5,440
12,063
17,608
18,818
19,125
20,036
20,954
42,234
64,952
61,674
69,014
70,788
75,515
74,993
77,656
75,785
Sales/Revenue/Turnover
3.91
2.97
5.5
5.34
6.6
6.34
5.84
9.23
6.3
6.25
5.64
6.35
6.42
6.45
5.03
4.56
4.98
Operating Margin (%)
110
108
182
182
197
218
236
245
301
592
644
677
744
929
875
895
- -
Depreciation Expense
267
288
729
980
1,194
1,300
1,508
2,062
3,441
3,189
2,915
3,720
3,967
4,056
2,835
2,983
2,802
Net Income, GAAP
14.72
10.45
12.98
18.08
17.47
17.37
19.86
15.01
12.07
16.65
17.32
15.97
15.66
16.66
16.82
17.05
16.14
Effective Tax Rate (%)
5.95
5.29
6.04
5.57
6.35
6.8
7.53
9.84
8.15
4.91
4.73
5.39
5.6
5.37
3.78
3.84
3.7
Profit Margin (%)
1,462
1,441
1,877
2,249
2,839
2,976
12,092
13,231
15,943
16,605
18,153
20,557
19,669
19,748
18,847
22,394
20,375
Working Capital
4
- -
24
- -
- -
- -
- -
35
1,014
- -
- -
- -
- -
- -
- -
- -
3,000
LT Debt
3,642
3,895
5,756
7,022
7,922
8,684
17,654
19,259
23,144
25,989
28,205
31,327
33,638
36,678
37,770
40,083
39,811
Total Equity
4.18
3.73
10.83
10.63
12.41
11.17
6.87
8.71
9.21
10.74
8.4
9.66
9.31
9.32
6.8
5.91
5.87
Return on Invested Capital (%)
14.09
13.21
22.39
23.85
25.49
23.09
23.07
26.71
25.84
16.38
13.27
14.35
13.75
13.39
8.83
8.63
7.33
Return on Capital (%)
15.66
14.98
28.52
29.24
29.95
27.3
26.04
28.93
37.62
27.44
21.32
23.42
21.38
19.1
12.32
12.31
11.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
10,646
11,978
12,886
LT Borrowings
2,806
2,098
2,581
LT Finance Leases
446
444
419
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,626
1,626
1,626
Market Capitalization
34,199
27,976
25,986

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
57,762
55,673
58,234
Cash, Cash Equivalents & STI
18,273
14,511
11,827
Accounts Receivable, Net
15,726
17,648
18,468
Inventories
12,812
10,823
11,317
Total Current Liabilities
38,916
36,109
37,859
Payables & Accruals
- -
- -
- -
ST Debt
10,646
11,978
12,886
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19%
7.32%
6.12%
Free Cash Flow
-174.9%
-363.14%
-163.62%
Net Income, GAAP
11.53%
2.32%
5.21%
Sales/Revenue/Turnover
18.36%
4.8%
3.55%
Total Cash Common Dividend
18.68%
7.48%
-26.8%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22,946
18,097
18,017
15,933
74,993
2025
22,473
19,361
16,050
- -
77,656
2026
23,278
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.2
- -
- -
- -
1.74
2025
1.12
- -
- -
- -
- -
2026
1.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
- -
- -
- -
1.38
2025
0.05
- -
- -
- -
- -
2026
0.06
- -
- -
- -
- -
Similar Companies
Landec Corporation (LNDC)
CEN Biotech, Inc. (CENBF)
Integrated Pharmaceuticals, Inc. (INTP)
West Island Brands Inc. (WIB.CN)
Lumiera Health Inc. (NHPHF)
High Sierra Technologies, Inc. (HSTI)
Business
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) engages primarily in the research, development, manufacture, and sale of Chinese patent medicines, chemical drugs, and biological products in China and internationally. The company operates through segments including proprietary Chinese medicines, chemical drugs, and healthcare products, offering a diverse portfolio encompassing cardiovascular drugs such as Compound Danshen Dripping Pills and Coronary Heart Granules; respiratory medications like Pediatric Gubenning Injection and Huoxiang Zhengqi Liquid; digestive treatments including Weishu Compound Tablets; and nutritional supplements, antibiotics, and OTC health products under brands like Baiyunshan and Kingold. It also provides pharmaceutical distribution services and raw material trading through subsidiaries. [ from previous context, assuming company info] Founded in 1993 and headquartered in Guangzhou, China, the company maintains extensive operations across mainland China with additional presence in Hong Kong and select international markets, targeting hospitals, pharmacies, and retail consumers in the healthcare sector. [web:previous] In recent developments, Guangzhou Baiyunshan Pharmaceutical Holdings expanded its portfolio through the launch of new proprietary Chinese medicine formulations in 2024 and formed strategic partnerships for innovative drug distribution amid China's healthcare reforms; it also completed a significant acquisition of regional manufacturing assets in early 2025 to bolster chemical drug production capacity, reflecting a shift toward integrated R&D and supply chain optimization.